Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Temporary Codes for Use with Outpatient Prospective Payment System
C9076 is a valid 2024 HCPCS code for Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose or just “Lisocabtagene car pos t” for short, used in Other medical items or services.
HCPCS Level II Code Temporary Codes for Use with Outpatient Prospective Payment System |
|
HCPCS Code | C9076 |
---|---|
Description |
Long description:
Short description: |
HCPCS Modifier1 | |
HCPCS Pricing indicator |
53 - Statute
|
Multiple pricing indicator |
A - Not applicable as HCPCS priced under one methodology
|
Statute number | 1833(t) |
Coverage code | D - Special coverage instructions apply |
BETOS2 code | O1E - Other drugs |
HCPCS Action code | N - No maintenance for this code |
Type of service | 9 - Other medical items or services |
Effective date | Effective Oct 01, 2021 |
Date added | Added Jul 01, 2021 |
Termination date | Sep 30, 2021 |
HCPCS Coding Procedures |
In HCPCS Level II, modifiers are composed of two alpha or alphanumeric characters.
Example: E0260-NU - Hospital bed, semi-electric (head and foot adjustment), with any type side rails, with mattress
“NU” identifies the hospital bed as new equipment
1 Two-digit numeric codes are Level I code modifiers copyrighted© by the American Medical Association's Current Procedural Terminology (CPT).
2 BETOS stands for “Berenson-Eggers Type Of Service”